[
    "{\"step_by_step_thinking\": \"Mogamulizumab is a monoclonal antibody that targets C-C chemokine receptor type 4 (CCR4), which is expressed on the surface of malignant T-cells. Cutaneous T-cell lymphoma (CTCL) is a type of non-Hodgkin lymphoma that primarily affects the skin. Given that mogamulizumab specifically targets CCR4, which is involved in the pathogenesis of CTCL, it is a potential treatment option for this condition. Therefore, the answer is yes.\", \"answer_choice\": \"A\"}"
]